AbClon Inc. (KOSDAQ:174900)

Market Cap	715.33B +340.4%
Revenue (ttm)	4.71B +101.5%
Net Income	-18.10B
EPS	-976.02
Shares Out	19.93M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	248,526
Average Volume	371,720
Open	36,600
Previous Close	36,550
Day's Range	33,600 - 36,600
52-Week Range	9,770 - 95,800
Beta	n/a
RSI	27.11
Earnings Date	n/a

About AbClon

AbClon Inc. engages in the research and development of antibody drugs in South Korea and Sweden. The company's products in pipeline include NEST platform technology products for breast and gastric cancers; AffiMab platform technology products for colon cancer and autoimmune diseases; and CAR-T platform technology products for hematologic and ovarian cancers. AbClon Inc. was founded in 2010 and is based in Seoul, South Korea.

• Industry: Specialty Business Services
• Sector: Industrials
• Founded: 2010
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 174900

Financial Performance

In 2025, AbClon's revenue was 4.71 billion, an increase of 101.47% compared to the previous year's 2.34 billion. Losses were -18.10 billion, 11.1% more than in 2024.